Drug
Pyrotinib clinical trials
Also written SHR1258.
Keep track of what changes. Save the pyrotinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- SHR1258
- 6
Studies by the year they started
112 studies that test it; most in 2019 (20); 1 more planned to start later
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 7 |
| 2019 | 20 |
| 2020 | 16 |
| 2021 | 13 |
| 2022 | 12 |
| 2023 | 10 |
| 2024 | 8 |
| 2025 | 9 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 96
Jiangsu HengRui Medicine Co., Ltd. (15) · Fudan University (14) · Henan Cancer Hospital (5) · Shanghai Jiao Tong University School of Medicine (5) · Tianjin Medical University Cancer Institute and Hospital (5) · Sun Yat-sen University (5) · The First Affiliated Hospital with Nanjing Medical University (5) · Chinese Academy of Medical Sciences (5)
Often tested with
Tested in the same studies.
Trastuzumab (25) · Albumin-Bound Paclitaxel (12) · Paclitaxel (12) · Capecitabine (12) · Dalpiciclib (12) · Fulvestrant (8) · Trastuzumab rezetecan (7) · Camrelizumab (7)
Studies
Open first, then newest update. How each study uses pyrotinib is read from its arms, and is right about nine times in ten.
Testing it · 113
- Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast CancerNot yet recruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07892274Written as Pyrotinib
- A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXdNot yet recruitingPhase 2Fujian Medical UniversityNCT07836257Written as Pyrotinib
- A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 MutationNot yet recruitingPhase 1/2RemeGen Co., Ltd.NCT05745740Written as Pyrotinib
- Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBCRecruitingPhase 3Shanghai Jiao Tong University School of MedicineNCT07797218Written as Pyrotinib
- Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerNot yet recruitingPhase 2Fujian Cancer HospitalNCT07766772Written as Pyrotinib
- GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast CancerRecruitingPhase 1/2Fudan UniversityNCT05575804Written as GQ1001+pyrotinib
- Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab FailureRecruitingPhase 1/2Tianjin Medical University Cancer Institute and HospitalNCT07708194Written as Pyrotinib
- Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast CancerRecruitingPhase 4Peking University People's HospitalNCT07600164Written as Pyrotinib
- Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted TherapyRecruitingPhase 3Fudan UniversityNCT07528716Written as SHR- A1811+ Pyrotinib
- Precision Medicine for Immunotherapy-Resistant Advanced Esophageal CancerNot yet recruitingPhase 2/3Peking University Cancer Hospital & InstituteNCT07653451Written as Dalpiciclib + Pyrotinib
- Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast CancerRecruitingPhase 3Fudan UniversityNCT07615751Written as Pyrotinib 320mg po qd d1-d21 q3w and Trastuzumab 600mg IH d1 q3w Combined with Dalpicicli 125mg po gd d1-d21 q4w
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as Pyrotinib
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingPhase 2Sun Yat-sen UniversityNCT06563999Written as Pyrotinib
- A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung CancerRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT05482568Written as SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingPhase 2Peking Union Medical CollegeNCT06145308Written as albumin-bound paclitaxel+trastuzumab+pyrotinib
- ctDNA in HER2+ EBC Neoadjuvant TreatmentRecruitingPhase 2Shanghai Jiao Tong University School of MedicineNCT07335081Written as pyrotinib
- The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 PositiveNot yet recruitingNot applicableTianjin Medical University Cancer Institute and HospitalNCT06495541Written as Pyrotinib
- Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast CancerRecruitingPhase 2Shanghai Jiao Tong University School of MedicineNCT07393425Written as Pyrotinib 320mg
- Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast CancerRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07340398Written as Pyrotinib
- Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung CancerRecruitingPhase 2Peking Union Medical College HospitalNCT05751018Written as Pyrotinib
See all 113 studies that test pyrotinib →
Given in every arm · 7 — pyrotinib is usual care beside what is tested
- Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast CancerRecruitingPhase 2Sun Yat-sen UniversityNCT07610720Written as Pyrotinib
- Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain MetastasesRecruitingPhase 2Henan Cancer HospitalNCT05769010Written as Pyrotinib
- SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized StudyNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07417241Written as Pyrotinib
- Study of SHR-A1811 Combined with Pyrotinib and Bevacizumab in Advanced Breast Cancer with Brain MetastasisRecruitingPhase 1/2Fudan UniversityNCT06718933Written as Pyrotinib
- RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 AlterationsNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06185400Written as pyrotinib
- Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast CancerStatus unknownPhase 2Zhiyong YuNCT04963595Written as Pyrotinib
- A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast CancerStatus unknownPhase 2Jinming YuNCT04095390Written as Pyrotinib
As the comparator · 1 — what is tested is compared with pyrotinib
Codes
What other systems call pyrotinib · ClinicalTrials.gg INT000789
- UNII (FDA) CJN36EQM0HPYROTINIBConfirmed FDA, Wikidata
- Wikidata Q27275495pyrotinibConfirmed FDA, Wikidata
- NCI Thesaurus C111895PyrotinibOne source FDA
- DrugBank DB14993One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | CJN36EQM0H | PYROTINIB | Confirmed FDA, Wikidata |
| Wikidata | Q27275495 | pyrotinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C111895 | Pyrotinib | One source FDA |
| DrugBank | DB14993 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.